PE20091693A1 - PROTEASE-ACTIVATED RECEPTOR 2 ANTAGONIST - Google Patents
PROTEASE-ACTIVATED RECEPTOR 2 ANTAGONISTInfo
- Publication number
- PE20091693A1 PE20091693A1 PE2009000397A PE2009000397A PE20091693A1 PE 20091693 A1 PE20091693 A1 PE 20091693A1 PE 2009000397 A PE2009000397 A PE 2009000397A PE 2009000397 A PE2009000397 A PE 2009000397A PE 20091693 A1 PE20091693 A1 PE 20091693A1
- Authority
- PE
- Peru
- Prior art keywords
- antagonist
- protease
- par2
- activated receptor
- antibody
- Prior art date
Links
- 229940118430 Protease-activated receptor-2 antagonist Drugs 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 abstract 1
- 208000006820 Arthralgia Diseases 0.000 abstract 1
- 208000010392 Bone Fractures Diseases 0.000 abstract 1
- 206010058019 Cancer Pain Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 206010017076 Fracture Diseases 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 101000603877 Homo sapiens Nuclear receptor subfamily 1 group I member 2 Proteins 0.000 abstract 1
- 101001098560 Homo sapiens Proteinase-activated receptor 2 Proteins 0.000 abstract 1
- 101000713170 Homo sapiens Solute carrier family 52, riboflavin transporter, member 1 Proteins 0.000 abstract 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 102100036863 Solute carrier family 52, riboflavin transporter, member 1 Human genes 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
REFERIDA A UN ANTAGONISTA DEL RECEPTOR 2 ACTIVADO CON PROTEASA (PAR2) TAL COMO UN ANTICUERPO ANTI-PAR2 HUMANO O UN FRAGMENTO DE UN ANTICUERPO QUE SE UNE AL ANTIGENO. DICHO ANTAGONISTA PAR2 PUEDE COMBINARSE CON OTRO AGENTE TERAPEUTICO TAL COMO UN INHIBIDOR DE CITOCINA, UN INHIBIDOR DE NGF, UNA COLCHICINA, UN CORTICOESTEROIDE, ENTRE OTROS. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DEL DOLOR INFLAMATORIO, POSTOPERATORIO, NEUROPATICO, POR FRACTURA, POR FRACTURA OSTEOPOROTICA, POR CANCER O DOLOR ARTICULAR POR GOTAREFERRING TO A PROTEASE (PAR2) ACTIVATED RECEPTOR 2 ANTAGONIST SUCH AS AN ANTI-PAR2 ANTIBODY OR AN ANTIGEN BINDING FRAGMENT OF AN ANTIBODY. SAID PAR2 ANTAGONIST CAN BE COMBINED WITH ANOTHER THERAPEUTIC AGENT SUCH AS A CYTOKINE INHIBITOR, A NGF INHIBITOR, A COLCHICINA, A CORTICOSTEROID, AMONG OTHERS. SUCH COMPOUNDS ARE USEFUL IN THE TREATMENT OF INFLAMMATORY, POSTOPERATIVE, NEUROPATHIC PAIN, FOR FRACTURE, FOR OSTEOPOROTIC FRACTURE, FOR CANCER OR JOINT PAIN FROM Gout
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3790808P | 2008-03-19 | 2008-03-19 | |
| US11915508P | 2008-12-02 | 2008-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20091693A1 true PE20091693A1 (en) | 2009-11-16 |
Family
ID=40718925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2009000397A PE20091693A1 (en) | 2008-03-19 | 2009-03-17 | PROTEASE-ACTIVATED RECEPTOR 2 ANTAGONIST |
Country Status (6)
| Country | Link |
|---|---|
| AR (1) | AR070911A1 (en) |
| CL (1) | CL2009000660A1 (en) |
| PE (1) | PE20091693A1 (en) |
| TW (1) | TW201002345A (en) |
| UY (1) | UY31723A (en) |
| WO (1) | WO2009117481A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214655B2 (en) * | 2001-05-21 | 2007-05-08 | Johnson & Johnson Consumer Companies, Inc. | Peptides and the use thereof in darkening the skin |
| US7888482B2 (en) | 2006-02-10 | 2011-02-15 | Amgen Inc. | Antibodies that bind PAR-2 |
| JO3246B1 (en) | 2009-09-09 | 2018-03-08 | Regeneron Pharma | High affinity human antibodies to human protease-activated receptor-2 |
| US9333152B2 (en) | 2011-11-04 | 2016-05-10 | Lipotec, S.A. | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions |
| EP3049418A1 (en) | 2013-09-25 | 2016-08-03 | Vertex Pharmaceuticals Incorporated | Imidazopyridazines useful as inhibitors of the par-2 signaling pathway |
| US20160000791A1 (en) | 2014-07-07 | 2016-01-07 | Mayo Foundation For Medical Education And Research | Par1 modulation to alter myelination |
| US20190298743A1 (en) * | 2016-05-20 | 2019-10-03 | Takeda Pharmaceutical Company Limited | Treatment of pain |
| US20190201454A1 (en) * | 2016-06-23 | 2019-07-04 | Mayo Foundation For Medical Education And Research | Par2 modulation to alter myelination |
| CR20190417A (en) | 2017-03-16 | 2019-12-06 | Medimmune Ltd | Anti-par2 antibodies and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996023225A1 (en) * | 1995-01-25 | 1996-08-01 | Cor Therapeutics, Inc. | Recombinant c140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor |
| US5629174A (en) * | 1993-07-26 | 1997-05-13 | Cor Therapeutics, Inc. | Recombinant C140 receptor |
| US20090035315A1 (en) * | 2004-06-17 | 2009-02-05 | Stephan Christgau | Method of Improving Treatments in Rheumatic and Arthritic Diseases |
-
2009
- 2009-03-16 AR ARP090100937A patent/AR070911A1/en unknown
- 2009-03-17 PE PE2009000397A patent/PE20091693A1/en not_active Application Discontinuation
- 2009-03-18 WO PCT/US2009/037504 patent/WO2009117481A1/en not_active Ceased
- 2009-03-18 CL CL2009000660A patent/CL2009000660A1/en unknown
- 2009-03-18 TW TW098108692A patent/TW201002345A/en unknown
- 2009-03-19 UY UY0001031723A patent/UY31723A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2009000660A1 (en) | 2010-04-16 |
| AR070911A1 (en) | 2010-05-12 |
| TW201002345A (en) | 2010-01-16 |
| WO2009117481A1 (en) | 2009-09-24 |
| UY31723A (en) | 2009-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20091693A1 (en) | PROTEASE-ACTIVATED RECEPTOR 2 ANTAGONIST | |
| PE20121563A1 (en) | ANTIBODIES THAT SPECIFICALLY BIND THE EPHA2 RECEIVER | |
| NI200800284A (en) | PHARMACEUTICAL COMPOSITIONS OF ANTAGONISTS OF THE ANTI-CD40 ANTIBODY | |
| MX2012004035A (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors. | |
| CL2013003214A1 (en) | Stable formulation comprising at least one monoclonal antibody that specifically binds to pcsk9, a buffer, a surfactant and at least one stabilizer; and its use to treat or prevent cholesterol-related diseases. | |
| EA200870425A1 (en) | APPLICATION OF GRP119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS AND RELATED COMBINED THERAPY | |
| NO2017019I1 (en) | Diarylhydantoin compound, pharmaceutical composition and use thereof | |
| CY1123240T1 (en) | ANTI-FGF23 ANTIBODY AND A PHARMACEUTICAL COMPOSITION CONTAINING IT | |
| CL2007002492A1 (en) | Compounds derived from bi-, tri or non-aromatic polycycles, inhibitors of the 11-beta-hydroxysteroid dehydrogenase enzyme type i; process of preparation of these; pharmaceutical composition that includes them; use in the treatment of diseases such as obesity, diabetes and dyslipidemia, among others. | |
| UY32926A (en) | COMPOUNDS AS ANTAGONISTS OF LISOPHOSPHATIDIC ACID RECEPTORS | |
| BR112017022772A2 (en) | Methods to Treat or Prevent Migraine Headache | |
| MX2022005330A (en) | MULTI-SPECIFIC UNION MOLECULES WITH SCFV AT THE NTERMINAL END. | |
| CL2008003694A1 (en) | Compounds derived from substituted heterocycle-2-carboxamide; pharmaceutical composition; pharmaceutical combination; and its use as inhibitors of dipeptidyl peptidase iv (dpp-iv) in the treatment of asthma, copd and allergic rhinitis. | |
| EA201101475A1 (en) | METHODS OF APPLICATION OF GPR119 RECEPTOR TO IDENTIFY CONNECTIONS THAT CAN BE USED TO INCREASE THE BONE MASS | |
| EA200870185A1 (en) | COMBINATION OF ANG2 AND VEGF INHIBITORS | |
| NO20092637L (en) | Methods of treatment | |
| DOP2009000281A (en) | SMALL MOLECULES CONTAINING BORO | |
| CL2011003147A1 (en) | Compounds derived from n- (1-4- (1h-pyrazol-5-yl) phthalazine-1-yl) piperidine-4-yl) benzamide; pharmaceutical composition that contains them, useful as antagonist of the hedgehog trajectory, in the treatment of cancer. | |
| PA8659301A1 (en) | COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE SANGUINEA CONCENTRATION OF GLP-1 | |
| EA201200204A1 (en) | CONTAINING ANTI-TELE FOR HER2 COMPOSITION FOR SCRAPTURE INTRODUCTION | |
| ECSP10010446A (en) | USE OF RANOLAZINE FOR THE TREATMENT OF PAIN | |
| CL2009000402A1 (en) | Substituted 2-amino-acetamide derived compounds; pharmaceutical composition; Useful in the treatment of lung diseases, rheumatic disease, autoimmune disease, among others. | |
| CL2009000368A1 (en) | 3- (amido or sulfonamido) -4- (4-substituted azinyl) benzamides or benzosulfonamides; the pharmaceutical composition that contains them; the use of the compounds; and a kit containing said components; Useful as inhibitors of the chemokine receptor cxcr3. | |
| UY30479A1 (en) | BENZOFUR- AND BENZOTIENOPIRIMIDINE MODULATORS OF THE H4 HISTAMINE RECEIVER | |
| EA201201457A1 (en) | ORGANIC COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE BETA SUB-UNIT OF EPITELIAL SODIUM CHANNELS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |